MASLD: a disease in flux

Alina M Allen¹, Juan Pablo Arab^{2

3}, Vincent Wai-Sun Wong^{4

5}

Affiliations

¹ Department of Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. allen.alina@mayo.edu.
² Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA. JuanPablo.Arab@vcuhealth.org.
³ Departamento de Gastroenterologia, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile. JuanPablo.Arab@vcuhealth.org.
⁴ Medical Data Analytics Centre, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China. wongv@mect.cuhk.edu.hk.
⁵ State Key Laboratory of Digestive Disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China. wongv@mect.cuhk.edu.hk.

Alina M Allen et al. Nat Rev Gastroenterol Hepatol. 2024 Nov.

. 2024 Nov;21(11):747-750.

doi: 10.1038/s41575-024-00990-5. Epub 2024 Oct 2.

Alina M Allen¹, Juan Pablo Arab^{2

3}, Vincent Wai-Sun Wong^{4

5}

¹ Department of Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. allen.alina@mayo.edu.
² Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA. JuanPablo.Arab@vcuhealth.org.
³ Departamento de Gastroenterologia, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile. JuanPablo.Arab@vcuhealth.org.
⁴ Medical Data Analytics Centre, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China. wongv@mect.cuhk.edu.hk.
⁵ State Key Laboratory of Digestive Disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China. wongv@mect.cuhk.edu.hk.

No abstract available

References

1. Loomba, R., Friedman, S. L. & Shulman, G. I. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 184, 2537–2564 (2021). - DOI - PubMed
1. Fabbrini, E. et al. Phase 1 trials of PNPLA3 siRNA in I148M homozygous patients with MAFLD. N. Engl. J. Med. 391, 475–476 (2024). - DOI - PubMed
1. Maeso-Díaz, R. et al. Targeting senescent hepatocytes using the thrombomodulin-PAR1 inhibitor vorapaxar ameliorates NAFLD progression. Hepatology 78, 1209–1222 (2023). - DOI - PubMed
1. Yashaswini, C. N. et al. Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatohepatitis. J. Hepatol. 81, 207–217 (2024). - DOI - PubMed
1. Arab, J. P., Arrese, M. & Trauner, M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease. Annu. Rev. Pathol. 13, 321–350 (2018). - DOI - PubMed